Synapse - Hematologic Malignancies, Division of

Results (13375)

Predictors of cytokine release syndrome and neurotoxicity in patients with large B-cell lymphoma and their impact on survival

Meeting Abstract

Shouval, R.; Strouse, C.; Kim, S.; Oloyede, T.; Ahmed, S.; Awan, F. T.; Bachanova, V.; Badar, T.; Barba, P.; Beitinjaneh, A. M.; more...
Blood (2023)

Fulltext@MSK | Save

Real-world evidence in the United States (US) of the impact of bridging therapy prior to axicabtagene ciloleucel (axi-cel) for the treatment of relapsed or refractory large B-cell lymphoma (R/R LBCL)

Meeting Abstract

Cook, M. R.; Shouval, R.; Perales, M. A.; Bezerra, E.; Niu, A.; Dahiya, S.; Nastoupil, L. J.; Jacobson, C. A.; Budde, L. E.; Olson, A. L.; more...
Blood (2023)

Fulltext@MSK | Save

ALLO-647 for lymphodepletion in the allogeneic CAR T setting: Safety experience with ALLO-501/501A in patients (pts) with relapsed/refractory (r/r) large B-cell and follicular lymphomas

Meeting Abstract

Locke, F. L.; Munoz, J. L.; Tees, M. T.; Lekakis, L. J.; Eradat, H. A.; de Vos, S.; Nath, R.; Stevens, D. A.; Malik, S. A.; Shouse, G. P.; more...
Blood (2023)

Fulltext@MSK | Save

Valemetostat for relapsed or refractory peripheral T-cell lymphomas: Primary results from a phase 1 trial

Meeting Abstract

Jacobsen, E.; Maruyama, D.; Porcu, P.; Tobinai, K.; Allen, P. B.; Ishitsuka, K.; Tsukasaki, K.; Kusumoto, S.; Foss, F. M.; Yamauchi, N.; more...
Blood (2023)

Fulltext@MSK | Save

Asciminib (ASC) in combination with Imatinib (IMA), nilotinib (NIL), or dasatinib (DAS) may be a potential treatment (Tx) option in patients (pts) with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase or accelerated phase (Ph + CML-CP/AP): Final results from the asciminib phase 1 study

Meeting Abstract

Cortes, J.; Lang, F.; Rea, D.; Hochhaus, A.; Breccia, M.; Goh, Y. T.; Heinrich, M. C.; Hughes, T. P.; Janssen, J. J. W. M.; le Coutre, P.; more...
Blood (2023)

Fulltext@MSK | Save

Post-transplant cyclophosphamide eliminates disparity in GvHD-free, relapse-free survival and overall survival between 8/8 matched and 7/8 mismatched unrelated donor hematopoietic cell transplantation in adults with hematologic malignancies

Meeting Abstract

Auletta, J. J.; Al Malki, M. M.; DeFor, T.; Shaffer, B. C.; Gooptu, M.; Bolanos-Meade, J.; Abboud, R.; Briggs, A. D.; Khimani, F.; Modi, D.; more...
Blood (2023)

Fulltext@MSK | Save

Comparable survival of treatment naive TP53 mutated acute myeloid leukemia treated with hypomethylating agent compared to hypomethylating agent plus venetoclax based therapy

Meeting Abstract

Badar, T.; Atallah, E. L.; Shallis, R. M.; Patel, A. A.; Correia, G. S. D. C.; Goldberg, A. D.; Saliba, A.; Bewersdorf, J. P.; Duvall, A. S.; Bradshaw, D.; more...
Blood (2023)

Fulltext@MSK | Save

(131)I-apamistamab-led allogeneic hematopoietic cell transplant significantly improves overall survival in patients with TP53 mutated R/R AML

Meeting Abstract

Choe, H.; Tomlinson, B. K.; Gyurkocza, B.; Nath, R.; Seropian, S.; Litzow, M. R.; Abboud, C. N.; Stiff, P. J.; Abhyankar, S.; Foran, J. M.; more...
Blood (2023)

Fulltext@MSK | Save

Clinical implications of TP53 mutations/allelic state in patients (Pts) with myelodysplastic syndromes/neoplasms (MDS) treated with hypomethylating agents (HMA)- a multicenter, retrospective analysis from the VALIDATE database

Meeting Abstract

Kewan, T.; Bewersdorf, J. P.; Blaha, O.; Stahl, M.; Al Ali, N. H.; DeZern, A. E.; Sekeres, M. A.; Carraway, H. E.; Desai, P.; Griffiths, E. A.; more...
Blood (2023)

Fulltext@MSK | Save

Intensive induction chemotherapy (IC) vs hypomethylating agents plus venetoclax (HMA/VEN) in IDH1-or IDH2-mutant newly diagnosed acute myeloid leukemia (AML) - A multicenter cohort study

Meeting Abstract

Bewersdorf, J. P.; Shimony, S.; Shallis, R. M.; Liu, Y.; Schaefer, E. J.; Zeidan, A. M.; Goldberg, A. D.; Stein, E. M.; Marcucci, G.; Lindsley, R. C.; more...
Blood (2023)

Fulltext@MSK | Save